Overview
Sponsor-declared trial summary
Phase
Phase I and Phase II (Integrated) - Other
Status
Ongoing, recruiting
Participants planned
1
Countries
1
Sites
1
Lung cancer (non-small cell lung cancer)
Key facts
- Sponsor
- Worldwide Innovative Network
- Participant type
- Patients
- Age range
- 65+ years
- Gender
- Male and Female
- Therapeutic area
- Diseases [C] - Neoplasms [C04]
- Trial duration
- 27 Sep 2022 → ongoing
- Decision date (initial)
- 2022-06-01
- Transition trial
- No
- Low-intervention
- No
- Rare-disease indication
- No
- Vulnerable population
- No
Trial design
CTIS Part I — objectives, methods, condition coding
Conditions and MedDRA coding
Lung cancer (non-small cell lung cancer)
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
Worldwide Innovative Network
- Sponsor organisation
- Worldwide Innovative Network
- Address
- 9 Rue Guy Moquet
- City
- Villejuif
- Postcode
- 94800
- Country
- France
Scientific contact point
- Organisation
- Worldwide Innovative Network
- Contact name
- Fanny Wunder
Public contact point
- Organisation
- Worldwide Innovative Network
- Contact name
- Fanny Wunder
Locations
1 EU/EEA country · 1 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| Spain | Ongoing, recruiting | 1 | 1 |
| Rest of world | — | 0 | — |
Investigational sites
Country notifications
Trial-start, recruitment-start, end and early-termination notifications submitted per Member State
| Country | Trial start | Trial end | Recruitment start | Recruitment end | Early termination |
|---|---|---|---|---|---|
| Spain | 2022-09-27 | 2023-07-04 | 2022-09-29 |
Application history
1 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2022-04-01 | Spain | Acceptable 2022-05-31
|
2022-06-01 |